Table 1.
Current direct KRAS-mutant inhibitors.
| Drug | Alternate Names | Manufacturer | Target | Development Stage |
|---|---|---|---|---|
| ARS-853 | Wellspring Biosciences | G12C | In vivo | |
| ARS-1620 | Wellspring Biosciences | G12C | In vivo | |
| AMG510 | Sotorasib | Amgen | G12C | FDA-approved |
| MRTX849 | Adagrasib | Mirati therapeutics | G12C | FDA-approved |
| MRTX-EX185 | Mirati therapeutics | G12D | In vivo | |
| MRTX-1133 | Mirati therapeutics | G12D | Phase ½ Clinical trials | |
| ASP2453 | Astellas Pharma Inc | G12C | In vivo | |
| RMC-6291 | Revolution Medicines | G12C | Phase 1 Clinical trial | |
| RMC-6236 | Revolution Medicines | G12C, G12D, G12V, G12X | In vivo (not published) | |
| RMC-036 | Revolution Medicines | G12D | In vivo (not published) | |
| RMC-037 | Revolution Medicines | G12D | In vivo (not published) | |
| BBO-8520 | Bridgebio Pharma | G12C | In vivo (not published) | |
| ERAS-3490 | Erasca | G12C | In vivo (not published) | |
| JDQ443 | Novartis | G12C | Phase 1–3 Clinical trials |